Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

INTRODUCTION: Predictive cancer biomarkers to guide the right treatment to the right patient at the right time are strongly needed. The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Munro, Alison F, Bartels, Annette, Balslev, Eva, Twelves, Christopher J, Cameron, David A, Brünner, Nils, Bartlett, John MS
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672718/
https://ncbi.nlm.nih.gov/pubmed/23570501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3411
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados